Hematological toxicity of [225Ac]Ac-PSMA-617 and [177Lu]Lu-PSMA-617 in RM1-PGLS syngeneic mouse model

Abstract Background Prostate cancer (PC) has a 34% 5-year survival rate after progressing to metastatic castration-resistant prostate cancer (mCRPC), which occurs in 20–30% of cases. Treatments like chemotherapy, immunotherapy, and PSMA-targeted radioligand therapy (RLT) show promise, but challenges...

Full description

Saved in:
Bibliographic Details
Main Authors: Meryl Maria Vilangattil, Abir Swaidan, Jonathan Godinez, Marco F. Taddio, Johannes Czernin, Christine E. Mona, Giuseppe Carlucci
Format: Article
Language:English
Published: SpringerOpen 2025-03-01
Series:EJNMMI Radiopharmacy and Chemistry
Subjects:
Online Access:https://doi.org/10.1186/s41181-025-00333-y
Tags: Add Tag
No Tags, Be the first to tag this record!